Metabolik Miyopatiler
Özet
Metabolik miyopatiler, kas enerji metabolizmasındaki enzimatik bozukluklara bağlı gelişen ve klinik yelpazesi egzersiz intoleransından sistemik tutuluma kadar uzanan heterojen kalıtsal hastalıklardır. Tanı süreci; detaylı klinik öykü, spesifik laboratuvar analizleri ve moleküler testlerin bir arada değerlendirilmesini gerektiren multidisipliner bir yaklaşım gerektirir. Tedavi stratejileri ise temel olarak diyet düzenlemeleri, tetikleyici faktörlerden kaçınma ve hastalığa özgü metabolik destek yöntemlerine dayanmaktadır.
Metabolic myopathies are heterogeneous hereditary conditions caused by enzymatic defects in muscle energy metabolism, manifesting as symptoms ranging from exercise intolerance to systemic involvement. Diagnosis requires a multidisciplinary approach combining clinical history, specific laboratory analysis, and molecular genetic testing. Management strategies primarily focus on dietary interventions, the avoidance of trigger factors, and the implementation of specific metabolic therapies tailored to the underlying deficiency.
Referanslar
Berardo A, DiMauro S, Hirano M. A diagnostic algorithm for metabolic myopathies. Curr Neurol Neurosci Rep. 2010;10(2):118-26.
Joshi PR, Zierz S. Muscle Carnitine Palmitoyltransferase II (CPT II) Deficiency: A Conceptual Approach. Molecules. 2020;25(8):1784-.
van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet. 2008;11;372(9646):1342-53.
Darras BT, Friedman NR. Metabolic myopathies: a clinical approach; part II. Pediatr Neurol. 2000;22(3):171-81.
Tarnopolsky, M.A. Metabolic Myopathies. Continuum (Minneap Minn). 2016;22:1829-51.
DiMauro S. Muscle glycogenoses: an overview. Acta Myol. 2007; 26:35–41.
McArdle B. Myopathy due to a defect in muscle glycogen breakdown. Clin Sci. 1951;10(1):13-35.
DiMauro S, Lamperti C. Muscle glycogenoses. Muscle Nerve 2001;24:984-99.
Andersen ST, Haller RG, Vissing J. Effect of oral sucrose shortly before exercise on work capacity in McArdle disease. Arch Neurol. 2008;65:786-9.
Tarui S. Glycolytic defects in muscle: aspects of collaboration between basic science and clinical medicine. Muscle Nerve 1995;3:2-9.
Nakajima H, Raben N, Hamaguchi T, et al. Phosphofructokinase deficiency; past, present and future. Curr Mol Med 2002;2:197-212.
Finsterer J. Update Review about Metabolic Myopathies. Life (Basel). 2020;10(4):43.
Hagemans ML, Winkel LP, Hop WC, Reuser AJ, Van Doorn PA, Van der Ploeg AT. Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology. 2005;64(12):2139-41.
Dlamini N, Jan W, Norwood F, et al. Muscle MRI findings in siblings with juvenile-onset acid maltase deficiency (Pompe disease). Neuromuscul Disord. 2008;18(5):408-9.
Pompe Disease Diagnostic Working Group, Winchester B, Bali D, et al. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genet Metab. 2008;93(3):275-81.
Kuperus E, Kruijshaar ME, Wens SCA, et al. Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study. Neurology. 2017;89:2365-73.
Vasiljevski ER, Summers MA, Little DG, Schindeler A. Lipid storage myopathies: Current treatments and future directions. Prog Lipid Res 2018;72:1-17.
Tobon A. Metabolic myopathies. Continuum (Minneap Minn). 2013;19(6):1571-97.
El-Gharbawy A, Vockley J. Inborn Errors of Metabolism with Myopathy: Defects of Fatty Acid Oxidation and the Carnitine Shuttle System. Pediatr Clin North Am. 2018;65(2):317-35.
Deschauer M, Wieser T, Zierz S. Muscle carnitine palmitoyltransferase II deficiency:clinical and molecular genetic features and diagnostic aspects. Arch Neurol 2005;62:37-41.
Olpin SE, Afifi A, Clark S, et al. Mutation and biochemical analysis in carnitine palmitoyltransferase type II (CPT II) deficiency. J Inherit Metab Dis 2003;26:543-57.
Longo N, di San Filipo CA, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 2006;142C:77-85.
Rubio-Gozalbo ME, Bakker JA, Waterham HR, et al. Carnitine acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects. Mol Aspects Med 2004;25:521-32.
Iafolla AK, Thompson RJ Jr, Roe CR. Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr 1994;124:409-15.
Den Boer MEJ, Dionisi-Vici C, Chakrapani A, et al. Mitochondrial trifunctional protein deficiency: a severe fatty acid oxidation disorder with cardiac and neurologic involvement. J Pediatr 2003;142:684-9.
Olsen RKJ, Olpin SE, Andresen BS, et al. ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain 2007;130:2045-54.
Adler M, Shieh PB. Metabolic Myopathies. Semin Neurol. 2015;35(4):385-97.
Zeharia A, Shaag A, Houtkooper R, et al. Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood. Am J Hum Genet 2008;83:489-94.
Tein I. Disorders of fatty acid oxidation. Handb Clin Neurol. 2013;113:1675-88.
Cohen BH. Mitochondrial and Metabolic Myopathies. Continuum (Minneap Minn). 2019;25(6):1732-1766.
Finsterer J. An update on diagnosis and therapy of metabolic myopathies. Expert Rev Neurother 2018;18:933-43.
Luna-Sánchez M, Hidalgo-Gutiérrez A, Hildebrandt TM, et al. CoQ deficiency causes disruption of mitochondrial sulfide oxidation, a new pathomechanism associated with this syndrome. EMBO Mol. Med. 2017;9:78-95.
Wang, J, Kim E, Dai H, et al. Clinical and molecular spectrum of thymidine kinase 2-related mtDNA maintenance defect. Mol. Genet. Metab. 2018;124:124-130.
Rowland TJ, Sweet ME, Mestroni L, Taylor MR. Danon disease - dysregulation of autophagy in a multisystem disorder with cardiomyopathy. J. Cell Sci. 2016; 129: 2135-43.
Munteanu I, Ramachandran N, Ruggieri A, Awaya T, Nishino I, Minassian BA. Congenital autophagic vacuolar myopathy is allelic to X-linked myopathy with excessive autophagy. Neurology 2015; 84: 1714-16.
Toscano A, Barca E, Musumeci O. Update on diagnostics of metabolic myopathies. Curr Opin Neurol. 2017;30(5):553-62.
Lilleker JB, Keh YS, Roncaroli F, Sharma R, Roberts M. Metabolic myopathies: a practical approach. Pract Neurol. 2018;18(1):14-26.
Smith EC, El-Gharbawy A, Koeberl DD. Metabolic myopathies: clinical features and diagnostic approach. Rheum Dis Clin North Am. 2011;37(2):201-vi.
Angelini C, Semplicini C. Metabolic myopathies: the challenge of new treatments. Curr Opin Pharmacol 2010;10:338-45.
